This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Stephen W. Lagakos, PhD
Harvard University Boston, Mass

Margaret A. Fischl, MD
University of Miami (Fla)

Daniel S. Stein, MD
National Institute of Allergy and Infectious Diseases Bethesda, Md

Paul A. Volberding, MD
University of California San Francisco

JAMA. 1992;267(18):2473.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.

—Hamilton et al state that the data provided in the articles by Lagakos et al¹ and Easterbrook et al² "are insufficient because they were unplanned and they either involved too few events for one to be comfortable with the conclusions or dealt with patients at more advanced stages of HIV disease, for whom the benefits of prompt zidovudine treatment have already been demonstrated."

The finding in the VA study that zidovudine may be ineffective in blacks and Hispanics was not specified before the data were examined, but rather noticed only after several subgroup analyses of their data. It is well known that results observed in this manner often are spurious,³ and Hamilton et al correctly caution about overinterpretation of this finding.

However, this bias is not applicable to the findings of Lagakos et al and Easterbrook et al because these analyses were motivated by an . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?